Loss of C/EBPα and Favorable Prognosis of Acute Myeloid Leukemias: A Biological Paradox
- 15 February 2004
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (4), 582-584
- https://doi.org/10.1200/jco.2004.12.965
Abstract
No abstract availableThis publication has 29 references indexed in Scilit:
- Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPα expressionBlood, 2004
- BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B StudyBlood, 2003
- Role of deferiprone in chelation therapy for transfusional iron overloadBlood, 2003
- Induction of C/EBPα activity alters gene expression and differentiation of human CD34+ cellsBlood, 2003
- Disruption of differentiation in human cancer: AML shows the wayNature Reviews Cancer, 2003
- Targeted inhibition of FLT3 overcomes the block to myeloid differentiation in 32Dcl3 cells caused by expression of FLT3/ITD mutationsBlood, 2002
- CCAAT/Enhancer binding proteins repress the leukemic phenotype of acute myeloid leukemiaBlood, 2002
- Calreticulin Interacts with C/EBPα and C/EBPβ mRNAs and Represses Translation of C/EBP ProteinsMolecular and Cellular Biology, 2002
- BCR-ABL suppresses C/EBPα expression through inhibitory action of hnRNP E2Nature Genetics, 2001
- c-Myc Is a Critical Target for C/EBPα in GranulopoiesisMolecular and Cellular Biology, 2001